机器人辅助根治性前列腺切除术中 Sentire® 和达芬奇® 系统的临床效果和成本效益。

IF 4.5 3区 医学 Q1 UROLOGY & NEPHROLOGY
Run-da Jiao, Zheng Wang, Xian-Gui Kong, Shou-Yan Tang, Dan Xia, Zhen-Jie Wu, Jian-Chao Liu, Li-Hua Liu
{"title":"机器人辅助根治性前列腺切除术中 Sentire® 和达芬奇® 系统的临床效果和成本效益。","authors":"Run-da Jiao, Zheng Wang, Xian-Gui Kong, Shou-Yan Tang, Dan Xia, Zhen-Jie Wu, Jian-Chao Liu, Li-Hua Liu","doi":"10.1590/S1677-5538.IBJU.2024.0706","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Robotic surgery has enhanced minimally invasive procedures with greater precision and control, but high costs have limited its widespread adoption. The Sentire® surgical system is hypothesized to achieve clinical outcomes comparable to those of the da Vinci® system while demonstrating superior cost-effectiveness in robot-assisted radical prostatectomy (RARP) procedures. This study aimed to compare RARP outcomes using Sentire® and da Vinci® ®, focusing on clinical efficacy and economic impact.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted at three high-volume urology centers in China, including 22 patients who underwent RARP with the Sentire® system and 287 patients who underwent RARP with the da Vinci® system. After 1:3 propensity score matching (PSM), 66 patients were successfully matched in the control group. Perioperative outcomes and cost metrics were assessed. Key measures included operative and console times, docking time, blood loss, recovery, positive surgical margins, surgeon evaluations of performance and comfort, and cost-effectiveness.</p><p><strong>Results: </strong>The Sentire® group had a longer median operative time (143 vs. 112 minutes, p=0.024), while console time (85 vs. 76 minutes, p=0.323) and docking time (9.0 vs. 6.0 minutes, p=0.279) were comparable. Blood loss was also similar between the groups (p=0.093). Positive surgical margin rates were 22.7% for Sentire® and 20.0% for da Vinci® (p=1.000), and no significant differences were observed in pathological ISUP grades or prostate volumes (p=0.327 and p=0.856, respectively). At 1-year follow-up, PSA recurrence was observed in 3 patients in the Sentire® group (4.5%) and 4 in the control group (6.1%) (p=0.625), with similar median PSA levels (0.012 vs. 0.014 ng/mL, p=0.410). Urinary continence rates were also comparable at 1, 3, and 12 months (all p > 0.05). Cost-effectiveness analysis revealed lower total and direct costs in the Sentire® group, including surgery expenses ($8,750 vs. $10,500, p=0.021), although differences in consumable and indirect costs were not statistically significant. Surgeon satisfaction scores for performance and comfort were slightly better for Sentire® but did not reach statistical significance (p > 0.05).</p><p><strong>Conclusion: </strong>This study demonstrates that the Sentire® system is well-suited for urological surgeries, offering comparable clinical outcomes and shorter hospital stays while improving cost-effectiveness compared to the da Vinci® system.</p>","PeriodicalId":49283,"journal":{"name":"International Braz J Urol","volume":"51 4","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236983/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Outcomes and Cost-effectiveness between the Sentire® and da Vinci® systems in Robot-assisted Radical Prostatectomy.\",\"authors\":\"Run-da Jiao, Zheng Wang, Xian-Gui Kong, Shou-Yan Tang, Dan Xia, Zhen-Jie Wu, Jian-Chao Liu, Li-Hua Liu\",\"doi\":\"10.1590/S1677-5538.IBJU.2024.0706\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Robotic surgery has enhanced minimally invasive procedures with greater precision and control, but high costs have limited its widespread adoption. The Sentire® surgical system is hypothesized to achieve clinical outcomes comparable to those of the da Vinci® system while demonstrating superior cost-effectiveness in robot-assisted radical prostatectomy (RARP) procedures. This study aimed to compare RARP outcomes using Sentire® and da Vinci® ®, focusing on clinical efficacy and economic impact.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted at three high-volume urology centers in China, including 22 patients who underwent RARP with the Sentire® system and 287 patients who underwent RARP with the da Vinci® system. After 1:3 propensity score matching (PSM), 66 patients were successfully matched in the control group. Perioperative outcomes and cost metrics were assessed. Key measures included operative and console times, docking time, blood loss, recovery, positive surgical margins, surgeon evaluations of performance and comfort, and cost-effectiveness.</p><p><strong>Results: </strong>The Sentire® group had a longer median operative time (143 vs. 112 minutes, p=0.024), while console time (85 vs. 76 minutes, p=0.323) and docking time (9.0 vs. 6.0 minutes, p=0.279) were comparable. Blood loss was also similar between the groups (p=0.093). Positive surgical margin rates were 22.7% for Sentire® and 20.0% for da Vinci® (p=1.000), and no significant differences were observed in pathological ISUP grades or prostate volumes (p=0.327 and p=0.856, respectively). At 1-year follow-up, PSA recurrence was observed in 3 patients in the Sentire® group (4.5%) and 4 in the control group (6.1%) (p=0.625), with similar median PSA levels (0.012 vs. 0.014 ng/mL, p=0.410). Urinary continence rates were also comparable at 1, 3, and 12 months (all p > 0.05). Cost-effectiveness analysis revealed lower total and direct costs in the Sentire® group, including surgery expenses ($8,750 vs. $10,500, p=0.021), although differences in consumable and indirect costs were not statistically significant. Surgeon satisfaction scores for performance and comfort were slightly better for Sentire® but did not reach statistical significance (p > 0.05).</p><p><strong>Conclusion: </strong>This study demonstrates that the Sentire® system is well-suited for urological surgeries, offering comparable clinical outcomes and shorter hospital stays while improving cost-effectiveness compared to the da Vinci® system.</p>\",\"PeriodicalId\":49283,\"journal\":{\"name\":\"International Braz J Urol\",\"volume\":\"51 4\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236983/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Braz J Urol\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1590/S1677-5538.IBJU.2024.0706\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Braz J Urol","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/S1677-5538.IBJU.2024.0706","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:机器人手术提高了微创手术的精确性和可控性,但高昂的成本限制了其广泛应用。据推测,Sentire®手术系统的临床效果可与达芬奇®系统媲美,同时在机器人辅助根治性前列腺切除术(RARP)中表现出更高的成本效益。本研究旨在比较Sentire®和达芬奇®的RARP疗效,重点关注临床疗效和经济影响:在中国三家大容量泌尿外科中心进行了一项回顾性分析,包括22名使用Sentire®系统进行RARP手术的患者和287名使用达芬奇®系统进行RARP手术的患者。经过1:3倾向评分匹配(PSM),66名患者成功匹配到对照组。对围手术期结果和成本指标进行了评估。关键指标包括手术和控制台时间、对接时间、失血量、恢复情况、手术切缘阳性率、外科医生对手术性能和舒适度的评价以及成本效益:结果:Sentire®组的中位手术时间更长(143 分钟对 112 分钟,P=0.024),而控制台时间(85 分钟对 76 分钟,P=0.323)和对接时间(9.0 分钟对 6.0 分钟,P=0.279)相当。两组的失血量也相似(P=0.093)。Sentire®和达芬奇®的手术切缘阳性率分别为22.7%和20.0%(p=1.000),病理ISUP分级和前列腺体积无明显差异(p=0.327和p=0.856)。随访一年时,Sentire®组有3名患者(4.5%)和对照组有4名患者(6.1%)出现PSA复发(p=0.625),PSA水平中位数相似(0.012 vs. 0.014 ng/mL,p=0.410)。1个月、3个月和12个月的尿失禁率也相当(p均大于0.05)。成本效益分析显示,Sentire® 组的总成本和直接成本较低,包括手术费用(8750 美元对 10500 美元,P=0.021),但消耗品和间接成本的差异无统计学意义。外科医生对 Sentire® 的性能和舒适度的满意度评分略高,但未达到统计学意义(P > 0.05):本研究表明,Sentire®系统非常适合泌尿外科手术,与达芬奇®系统相比,其临床效果相当,住院时间更短,成本效益更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical Outcomes and Cost-effectiveness between the Sentire® and da Vinci® systems in Robot-assisted Radical Prostatectomy.

Clinical Outcomes and Cost-effectiveness between the Sentire® and da Vinci® systems in Robot-assisted Radical Prostatectomy.

Clinical Outcomes and Cost-effectiveness between the Sentire® and da Vinci® systems in Robot-assisted Radical Prostatectomy.

Objective: Robotic surgery has enhanced minimally invasive procedures with greater precision and control, but high costs have limited its widespread adoption. The Sentire® surgical system is hypothesized to achieve clinical outcomes comparable to those of the da Vinci® system while demonstrating superior cost-effectiveness in robot-assisted radical prostatectomy (RARP) procedures. This study aimed to compare RARP outcomes using Sentire® and da Vinci® ®, focusing on clinical efficacy and economic impact.

Materials and methods: A retrospective analysis was conducted at three high-volume urology centers in China, including 22 patients who underwent RARP with the Sentire® system and 287 patients who underwent RARP with the da Vinci® system. After 1:3 propensity score matching (PSM), 66 patients were successfully matched in the control group. Perioperative outcomes and cost metrics were assessed. Key measures included operative and console times, docking time, blood loss, recovery, positive surgical margins, surgeon evaluations of performance and comfort, and cost-effectiveness.

Results: The Sentire® group had a longer median operative time (143 vs. 112 minutes, p=0.024), while console time (85 vs. 76 minutes, p=0.323) and docking time (9.0 vs. 6.0 minutes, p=0.279) were comparable. Blood loss was also similar between the groups (p=0.093). Positive surgical margin rates were 22.7% for Sentire® and 20.0% for da Vinci® (p=1.000), and no significant differences were observed in pathological ISUP grades or prostate volumes (p=0.327 and p=0.856, respectively). At 1-year follow-up, PSA recurrence was observed in 3 patients in the Sentire® group (4.5%) and 4 in the control group (6.1%) (p=0.625), with similar median PSA levels (0.012 vs. 0.014 ng/mL, p=0.410). Urinary continence rates were also comparable at 1, 3, and 12 months (all p > 0.05). Cost-effectiveness analysis revealed lower total and direct costs in the Sentire® group, including surgery expenses ($8,750 vs. $10,500, p=0.021), although differences in consumable and indirect costs were not statistically significant. Surgeon satisfaction scores for performance and comfort were slightly better for Sentire® but did not reach statistical significance (p > 0.05).

Conclusion: This study demonstrates that the Sentire® system is well-suited for urological surgeries, offering comparable clinical outcomes and shorter hospital stays while improving cost-effectiveness compared to the da Vinci® system.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Braz J Urol
International Braz J Urol UROLOGY & NEPHROLOGY-
CiteScore
4.60
自引率
21.60%
发文量
246
审稿时长
6-12 weeks
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信